NCT01117233View on ClinicalTrials.gov

Study In Healthy Adult Volunteers To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
Healthy
Interventions
DRUG

PF-04427429

single intravenous infusion of 10 mg PF-04427429 or placebo

DRUG

PF-04427429

single intravenous infusion of 30 mg PF-04427429 or placebo

DRUG

PF-04427429

single intravenous infusion of 100 mg PF-04427429 or placebo

DRUG

PF-04427429

single intravenous infusion of 300 mg PF-04427429 or placebo

DRUG

PF-04427429

single intravenous infusion of 1000 mg PF-04427429 or placebo

Trial Locations (1)

1070

Pfizer Investigational Site, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY